Status:
RECRUITING
Angiomammography and Neoadjuvant Chemotherapy
Lead Sponsor:
CHU de Quebec-Universite Laval
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The best prognostic factor following neoadjuvant chemotherapy is the pathological complete response (pCR). pCR is defined as the absence of invading cells in the breast and lymph nodes following neoad...
Eligibility Criteria
Inclusion
- Female aged 18 and over
- Histologically proven breast cancer by large gauge needle
- No evidence of distant metastasis
- Neoadjuvant chemotherapy with or without concomitant targeted therapy
- Breast tumor initially measurable by clinical examination
Exclusion
- Refusal to perform the biopsy or surgery
- Pregnant or possibly pregnant woman
- Usual contraindication to contrast product
- Significant kidney failure
- Allergy to contrast medium
- frank hyperthyroidism
- Usual contraindications to MRI
Key Trial Info
Start Date :
January 3 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05402930
Start Date
January 3 2018
End Date
December 1 2025
Last Update
March 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St-Sacrement Hospital
Québec, Quebec, Canada, G1S4L8